Article3 Biotech2026
Modulation of glycation, inflammation, and detoxification pathways by D-Galactose through the RAGE-NF-κB-Nrf2 signaling axis in liver and kidney of Wistar rats.
Article in 3 Biotech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
D-galactose (D-Gal) is used to induce aging-associated pathological complications; however, its dose-dependent effects on RAGE-NF-κB and Nrf2 pathways remain unexplored. We examine the effects of D-Gal (400, 500, and 600 mg/kg body weight) on glycation, inflammation, and detoxification parameters in the liver and kidney tissues of Wistar rats. Rats received subcutaneous D-Gal injections for 56 days, while the control rats received 0.9% saline. Blood samples were collected at 15-day intervals, and renal function was assessed using 24-h urine samples. After treatment, rats were sacrificed, liver and kidney tissues were harvested. D-Gal administration altered liver and kidney function by a dose-dependent increase in creatinine excretion upto 1.3-fold. Histological analysis revealed glomerular hypertrophy and hepatocellular injury. Additionally, an increase in GFR by 1.8-fold was observed (p < 0.05). D-Gal treatment showed a time-dependent increase in fructosamine (day 15), protein carbonyl content (day 30), and advanced glycation end products (AGEs) by day 56, accompanied by reduced free amino and thiol groups. Similar trends were observed in tissues, with D-Gal 500 showing the most pronounced effects (p < 0.001). Antioxidant and detoxification parameters exhibited time-dependent alterations, with changes in GSH levels and catalase activity in tissues (p < 0.001). D-Gal treatment significantly modulated RAGE and NF-κB expression at the gene and protein levels. D-Gal 600 induced a 7.5-fold increase in RAGE expression (p < 0.0001). NF-κB and Nrf2 expression were concentration-dependent, with changes at the protein level. Overall, D-Gal 500 exerted maximal effects via the RAGE-NF-κB-Nrf2 axis without significant cellular damage. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-026-04988-5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.